

D1
CONT.
SUB E1
CONT.

NO:3), TCCATGACGATCCTGATGCT (SEQ ID NO:87), TCCATGACGTCCTGATGCT (SEQ ID NO:39), TCCATGTCGTTCCCTGATGCT (SEQ ID NO:38), TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:46), TCGTCGTTGTCGTTGTCGTT (SEQ ID NO:47), TCCATGACGGTCCTGATGCT (SEQ ID NO:35), TCCATGACGCTCCTGATGCT (SEQ ID NO:88), TCCATGACGTTCCCTGATGCT (SEQ ID NO:7), TCCATCACGTGCCTGATGCT (SEQ ID NO:40), TCGTCGTTGTCGTTTTGTCGTT (SEQ ID NO:49), GCGTCCGTTGTCGTTGTCGTT (SEQ ID NO:56), TGTCGTTTGTCTGTTTGTCTGTT (SEQ ID NO:48), TGTCGTTGTCGTTGTCGTT (SEQ ID NO:50), TCGTCGTCGTCGTT (SEQ ID NO:51), TCCTGTCGTTCCCTGTCGTT (SEQ ID NO:52), TCCTGTCGTTTTTTGTCTGTT (SEQ ID NO:53), TCGTCGCTGTCTGCCCTTCTT (SEQ ID NO:54), and TCGTCGCTGTTGTCGTTTCTT (SEQ ID NO:55).

58. (Amended) The method of claim 42, wherein the immunostimulatory nucleic acid has a sequence including at least the following nucleotides TCCATGTCGCTCCTGATGCT (SEQ ID NO:37).

J

59. (Amended) The method of claim 42, wherein the immunostimulatory nucleic acid has a sequence including at least the following nucleotides TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:46).

D2
SUB E3

79. (Amended) The method of claim 60, wherein the immunostimulatory nucleic acid has a sequence selected from the group of sequences including at least the following nucleotides TCCATGTCGCTCCTGATGCT (SEQ ID NO:37), TCCATAACGTTCCCTGATGCT (SEQ ID NO:3), TCCATGACGATCCTGATGCT (SEQ ID NO:87), TCCATGACGTCCTGATGCT (SEQ ID NO:39), TCCATGTCGTTCCCTGATGCT (SEQ ID NO:38), TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:46), TCGTCGTTGTCGTTGTCGTT (SEQ ID NO:47), TCCATGACGGTCCTGATGCT (SEQ ID NO:35), TCCATGACGCTCCTGATGCT (SEQ ID NO:88), TCCATGACGTTCCCTGATGCT (SEQ ID NO:7), TCCATCACGTGCCTGATGCT (SEQ ID NO:40), TCGTCGTTGTCGTTTTGTCGTT

D2
CONT

(SEQ ID NO:49), GCGTGCGTTGTCGTTGTCGTT (SEQ ID NO:56),
TGTCGTTTGTGCTTTGTCGTT (SEQ ID NO:48), TGTCGTTGTCGTTGTCGTT (SEQ ID
NO:50), TCGTCGTCGTCGTT (SEQ ID NO:51), TCCTGTCGTTTCCTTGTCGTT (SEQ ID
NO:52), TCCTGTCGTTTTTTGTCGTT (SEQ ID NO:53), TCGTCGCTGTCTGCCCTTCTT
(SEQ ID NO:54), and TCGTCGCTGTTGTCGTTTCTT (SEQ ID NO:55).

80. (Amended) The method of claim 60, wherein the immunostimulatory nucleic acid
has a sequence including at least the following nucleotides TCCATGTCGCTCCTGATGCT
(SEQ ID NO:37).

SUB E3
cont.

81. (Amended) The method of claim 60, wherein the immunostimulatory nucleic acid
has a sequence including at least the following nucleotides
TCGTCGTTTGTGCTTTTGTGCGTT (SEQ ID NO:46).

82. (Amended) A method for treating asthma in a subject, comprising
administering to an asthmatic subject an effective amount for treating asthma in a subject
of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid, has a
sequence selected from the group of sequences including at least the following nucleotides
TCCATGTCGATCCTGATGCT (SEQ ID NO:36), TCCATGTCGGTCCTGATGCT (SEQ ID
NO:28), and GGGGTCAACGTTGAGGGGGG (SEQ ID NO:12).

D3

85. (Amended) The method of claim 82, wherein the immunostimulatory nucleic acid
has a sequence including at least the following nucleotides GGGGTCAACGTTGAGGGGGG
(SEQ ID NO:12).

SUB E4

86. (Amended) A method for desensitizing a subject against the occurrence of an
allergic reaction in response to contact with an allergen, comprising administering to a subject an
effective amount for desensitizing the subject against the occurrence of an allergic reaction of an